This Article Full Text Full Text (PDF) All Versions of this Article: 115/16/2153    most recent CIRCULATIONAHA.106.661041v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonderman, D. Articles by Lang, I. M. Search for Related Content PubMed PubMed Citation Articles by Bonderman, D. Articles by Lang, I. M. Related Collections Pulmonary circulation and disease Related Article

(Circulation. 2007;115:2153-2158.)
© 2007 American Heart Association, Inc.

Hypertension

Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension

Diana Bonderman, MD; Nika Skoro-Sajer, MD; Johannes Jakowitsch, PhD; Christopher Adlbrecht, MD; Daniela Dunkler, MSc; Sharokh Taghavi, MD; Walter Klepetko, MD; Meinhard Kneussl, MD; Irene M. Lang, MD

From the Departments of Cardiology (D.B., N.S.-S., J.J., C.A., I.M.L.), Core Unit for Medical Statistics and Informatics (D.D.), and Cardiothoracic Surgery (S.T., W.K.), Medical University of Vienna, and the Department of Pulmonology, Wilhelminenspital (M.K.), Vienna, Austria.

Correspondence to Irene M. Lang, MD, Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. E-mail irene.lang{at}meduniwien.ac.at

Received August 28, 2006; accepted March 2, 2007.

Background— Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by intraluminal thrombus organization and fibrous obliteration of pulmonary arteries. Recently, associated medical conditions such as splenectomy, ventriculoatrial shunt for the treatment of hydrocephalus, permanent central intravenous lines, inflammatory bowel disease, and osteomyelitis were found to be associated with the development of CTEPH. The study aim was to define the impact of these novel risk factors on survival.

Methods and Results— Between January 1992 and December 2006, 181 patients diagnosed with CTEPH were tracked with the use of our center’s customized computer database. A Cox regression model was used to examine relations between survival and associated medical conditions, age, sex, hemodynamic parameters, modified New York Heart Association functional class at diagnosis, CTEPH type, pulmonary endarterectomy, and anti-cardiolipin antibodies/lupus anticoagulant. During a median observation time of 22.1 (range, 0.03 to 152) months, the clinical end point of cardiovascular death or lung transplantation occurred in 48 cases (27%). Pulmonary endarterectomy (hazard ratio, 0.14; 95% CI, 0.05 to 0.41; P=0.0003), associated medical conditions (hazard ratio, 3.17; 95% CI, 1.70 to 5.92; P=0.0003), and pulmonary vascular resistance (hazard ratio, 1.02; 95% CI, 1.00 to 1.04; P=0.04) were predictors of survival. Thirty-day postoperative mortality (24% versus 9%) and the incidence of postoperative pulmonary hypertension (92% versus 20%) were substantially higher in patients with associated medical conditions.

Conclusions— CTEPH-predisposing medical conditions, such as splenectomy, permanent central intravenous lines, and certain inflammatory disorders, predict poor survival in CTEPH.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2007 115: 2087. [Full Text]

This article has been cited by other articles:

				R. Condliffe, D. G. Kiely, J. S. R. Gibbs, P. A. Corris, A. J. Peacock, D. P. Jenkins, D. Hodgkins, K. Goldsmith, R. J. Hughes, K. Sheares, et al. Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1122 - 1127. [Abstract] [Full Text] [PDF]

				M. Lankeit, C. Dellas, A. Panzenbock, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schafer, M. Puls, S. Konstantinides, and I. M. Lang Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension Eur. Respir. J., May 1, 2008; 31(5): 1024 - 1029. [Abstract] [Full Text] [PDF]

				D. Bonderman, J. Jakowitsch, B. Redwan, H. Bergmeister, M.-K. Renner, H. Panzenbock, C. Adlbrecht, A. Georgopoulos, W. Klepetko, M. Kneussl, et al. Role for Staphylococci in Misguided Thrombus Resolution of Chronic Thromboembolic Pulmonary Hypertension Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 678 - 684. [Abstract] [Full Text] [PDF]